

Table SV. Most preferred treatment options

Best treatment	n (% of all participants) ^a	n/n who ever received the medication (%)	Subgroup analysis according to PsA		
			n/n who ever received the medication without PsA (%)	n/n who ever received the medication with PsA (%)	p ^c
Topical treatment	22 (11.5)	22/186 (11.8)	21/143 (14.7)	1/43 (2.3)	0.028
Phototherapy ^b	24 (12.6)	24/156 (15.4)	23/119 (19.3)	1/37 (2.7)	0.014
UVB 311 nm	12 (6.3)	12/83 (14.5)	12/64 (18.8)	0/19 (0)	0.041
Topical PUVA	8 (4.2)	8/76 (10.5)	7/60 (11.7)	1/16 (6.3)	0.530
Systemic PUVA	1 (0.5)	1/26 (3.8)	1/22 (4.5)	0/4 (0)	0.664
Broad band UVB/SUP	3 (1.6)	3/31 (9.7)	3/23 (13)	0/8 (0)	0.282
Traditional systemic therapy ^c	59 (30.9)	59/148 (39.9)	50/108 (46.3)	9/40 (22.5)	0.009
Acitretin	10 (5.2)	10/30 (33.3)	10/27 (37)	0/3 (0)	0.197
Fumaric acid	26 (13.6)	26/88 (29.5)	26/76 (34.2)	0/12 (0)	0.016
Methotrexate	18 (9.4)	18/92 (19.6)	9/54 (16.7)	9/38 (23.7)	0.403
Ciclosporin	1 (0.5)	1/13 (7.7)	1/9 (11.1)	0/4 (0)	0.488
Alitretinoin	4 (2.1)	4/8 (50)	4/8 (50)	0/0	n.d.
Biologicals ^d	86 (45)	86/92 (93.5)	53/57 (93)	33/35 (94.3)	0.806
Adalimumab	36 (18.8)	36/55 (65.5)	23/33 (69.7)	13/22 (59.1)	0.418
Etanercept	8 (4.2)	8/23 (34.8)	4/11 (36.4)	4/12 (33.3)	0.879
Golimumab	3 (1.6)	3/4 (75)	0/1 (0)	3/3 (100)	0.250
Infliximab	14 (7.3)	14/19 (73.7)	4/7 (57.1)	10/12 (83.3)	0.211 ^e
Ustekinumab	25 (13.1)	25/28 (89.3)	22/24 (91.7)	3/4 (75)	0.318

^aNine participants chose a treatment that they had never received before as their best treatment ever, because they misunderstood the question. These participants were excluded. Data are based on the remaining 191 participants who answered correctly.

^bFive respondents had been treated with excimer laser but none of them indicated it as preferred treatment option. Seven participants had received another kind of phototherapy but did not prefer it.

^cTwo participants had previously obtained leflunomid, one systemic corticosteroids and one mycophenolate mofetil. However, none of these medications was designated as preferred option.

^dSeven participants had experience with another biological (alefacept: n=1, efalizumab: n=5, unknown: n=1), but none of them preferred this medication.

^eSubgroup analyses comparing preferences of participants with and without psoriatic arthritis were performed with χ^2 test or with Fisher's Exact Test (*).

n.d.: not determined (due to n=0 in the subgroup with PsA); PUVA: psoralen plus UVA; PsA: psoriatic arthritis; SUP: selective ultraviolet phototherapy.